Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy

Autor: Matthew J. Kempton, Kateryna Bulatova, Guido Gonzalez, Carlos Guevara, Nicolas Crossley, Gareth J. Barker
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Zdroj: Parkinson's Disease, Vol 2016 (2016)
Guevara, C, Bulatova, K, Barker, G J, Gonzalez, G, Crossley, N & Kempton, M J 2016, ' Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy ', Parkinson's disease, vol. 2016, 9631041 . https://doi.org/10.1155/2016/9631041
Parkinson's Disease
ISSN: 2042-0080
2090-8083
Popis: In multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease (IPD), MSA, and PSP. Ten healthy controls, 20 IPD, 12 PSP, and 8 MSA patients were studied using a volumetric MRI technique (SIENA). In controls, the a-WBAR was0.37%±0.28(CI 95% 0.17–0.57), while in IPD a-WBAR was0.54%±0.38(CI 95% 0.32–0.68). The IPD patients did not differ from the controls. In PSP, the a-WBAR was1.26%±0.51(CI 95%: 0.95–1.58). In MSA, a-WBAR was1.65%±1.12(CI 95%: 0.71–2.59). MSA did not differ from PSP. The a-WBAR in PSP and MSA were significantly higher than in the IPD group (p=0.004andp<0.001, resp.). In PSP, the use of a-WBAR required one-half of the patients needed for clinical scales to detect a 50% reduction in their progression. In MSA, one-quarter of the patients would be needed to detect the same effect. a-WBAR is a reasonable candidate to consider as a surrogate endpoint in short clinical trials using smaller sample sizes. The confidence intervals for a-WBAR may add a potential retrospective application for a-WBAR to improve the diagnostic accuracy of MSA and PSP versus IPD.
Databáze: OpenAIRE
Externí odkaz: